Our results also demonstrated that in the entire population, those T2D patients with A1c of 7% or better (group III and some in group II) have bone turnover (osteocalcin and CTx) that is not different from those without T2D, i.e., group I. While this finding suggests that not all patients with T2D will have low bone turnover, this also implies that it is not the diagnosis of T2D itself but the glycemic control that determines bone complications from T2D. This evidence concerns the gene CYP27A1 and type 2 diabetes mellitus.